Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations

Hematological Malignancy, Signal Transduction, Receptor Tyrosine Kinase +9

A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders

Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.4K citations · Full text

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Hematological Malignancy, Acquired Mutation, Receptor Tyrosine Kinase +9

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Hematological Malignancy, Polycythemia Vera, Essential Thrombocythemia +11

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6